Table of Contents
Introduction
The Global Preeclampsia Diagnostics Market is projected to grow from USD 2.2 billion in 2024 to approximately USD 5.8 billion by 2034. This reflects a robust compound annual growth rate (CAGR) of 10.2% during the forecast period. Growth is primarily driven by the rising global burden of hypertensive pregnancy disorders, improved diagnostic technologies, and expanded screening programs. Preeclampsia remains a major contributor to maternal and fetal morbidity and mortality, especially in low-resource regions. Early diagnosis can help reduce these complications and support better pregnancy outcomes.
One of the key technological advances fueling this market is biomarker testing. In particular, the ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) has gained clinical importance. For example, the Elecsys sFlt-1/PlGF ratio test has shown promising results, with a sensitivity of 91.4% and a specificity of 77.3% at a cutoff of 38. This test is useful for predicting the risk of developing severe preeclampsia within one week among pregnant women hospitalized with hypertension between 23 and 34 weeks of gestation.
Rising global awareness regarding maternal health is another strong growth factor. Preeclampsia accounts for a significant portion of maternal deaths. The Centers for Disease Control and Prevention (CDC) estimates that preeclampsia causes over 70,000 maternal deaths and around 500,000 fetal deaths each year. These figures have led healthcare providers and policymakers to prioritize timely diagnostics and interventions. As awareness increases, more women are undergoing routine antenatal screenings, which is supporting market expansion.
Government organizations are playing a crucial role in strengthening diagnostic access and awareness. The World Health Organization (WHO) has emphasized the need for better preeclampsia diagnostics through its target product profiles and clinical guidance. WHO guidelines recommend routine screening for blood pressure and proteinuria during every antenatal visit. Such protocols are being adopted by national health systems, further integrating diagnostics into standard maternal care.
Key Takeaways
- In 2023, the global preeclampsia diagnostics market generated US$ 2.2 billion in revenue and is projected to reach US$ 5.8 billion by 2033.
- The market is growing at a compound annual growth rate (CAGR) of 10.2% during the forecast period from 2023 to 2033.
- Based on product type, consumables accounted for the largest share in 2023, contributing approximately 57.6% of the total market revenue.
- Among test types, blood tests dominated with a 48.3% share, indicating strong reliance on biomarker-based detection for preeclampsia diagnosis.
- Hospitals emerged as the leading end-user segment, securing a 52.9% revenue share due to widespread adoption of diagnostic testing in clinical settings.
- North America led the regional market in 2023, holding a 38.6% share, driven by advanced healthcare infrastructure and increased maternal health awareness.
Emerging Trends
- Biomarker-Based Blood Tests: New blood tests can detect preeclampsia earlier by checking specific proteins linked to placental health. One such test, approved by the U.S. FDA, measures the levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1). These biomarkers are strong indicators of preeclampsia. The test can predict the risk of severe preeclampsia within two weeks. It offers an accuracy rate of around 94%. This early warning system helps doctors monitor high-risk pregnancies more effectively. Early detection allows for faster decisions and better outcomes for both mother and baby.
- First-Trimester Risk Assessment: Screening tools are now available to assess preeclampsia risk as early as 11 to 14 weeks of pregnancy. These tests use a combination of biomarkers, such as PlGF and pregnancy-associated plasma protein-A (PAPP-A). Blood pressure levels and uterine artery Doppler readings are also included in the analysis. Together, these indicators help identify women at high risk of developing preeclampsia. Early detection means that doctors can begin preventive care sooner. This trend improves the chances of managing the condition before it becomes dangerous.
- Wearable Monitoring Devices: Wearable technology is helping to track blood pressure in real time. Smart bracelets designed for pregnant women can detect early signs of hypertension. These devices work continuously and offer comfort and convenience. If abnormal readings are noticed, healthcare providers can act quickly. This technology is especially useful in rural or underserved areas where frequent check-ups may be difficult. Wearables allow pregnant women to stay connected with their care teams. This early warning system supports safer pregnancies and timely interventions.
- Machine Learning for Risk Prediction: Machine learning is now being used to predict preeclampsia risks. These advanced models analyze large amounts of health data. Factors like medical history, lab test results, and blood pressure readings are evaluated. The models then provide personalized risk scores for each patient. This helps doctors plan preventive care and manage complications more effectively. Research shows that machine learning can improve accuracy over traditional risk assessment methods. These tools are supporting better outcomes by enabling targeted care for those most at risk.
Use Cases
- Routine Prenatal Checkups: During regular prenatal checkups, doctors check the mother’s blood pressure and urine protein levels. These two indicators are important for identifying preeclampsia early. When detected in the initial stages, preeclampsia can be managed with medication, lifestyle changes, or increased monitoring. Early treatment helps reduce health risks for both the mother and the baby. If left unchecked, preeclampsia can lead to complications such as organ damage or premature birth. Therefore, routine diagnostic screening during prenatal visits is essential. It ensures prompt medical attention and better outcomes. These standard tests are widely available and form a cornerstone of safe maternity care.
- High-Risk Pregnancy Management: Some pregnant women are more likely to develop preeclampsia. These include women with obesity, diabetes, chronic hypertension, or a past history of preeclampsia. For these high-risk individuals, early diagnostic screening is recommended. Blood tests and biomarker screenings are used to assess risk levels. Once a risk is identified, doctors can provide closer monitoring and early interventions. Preventive care may include low-dose aspirin or frequent follow-up visits. This proactive approach can delay or prevent the onset of severe preeclampsia. Early diagnosis and targeted care greatly reduce health complications for both mother and baby in high-risk pregnancies.
- Hospital-Based Interventions: When preeclampsia symptoms appear, hospitals rely on advanced diagnostics. Blood tests, including the sFlt-1/PlGF ratio test, help assess severity. These tests can detect early organ stress or changes in placental function. Doctors use the results to make fast decisions about treatment or delivery timing. Immediate medical response can reduce serious health risks, such as seizures, kidney damage, or fetal distress. Hospital-based diagnostics are especially important in moderate to severe cases. They allow for quick intervention and close monitoring. With timely diagnosis and care, hospitals play a key role in managing critical preeclampsia cases safely.
- Remote Monitoring in Rural Areas: In rural or underserved areas, access to hospitals may be limited. To bridge this gap, remote monitoring solutions are increasingly used. Wearable devices track blood pressure and heart rate continuously. Telemedicine platforms allow real-time communication between pregnant women and healthcare providers. If abnormal readings are detected, medical teams are alerted immediately. This ensures that preeclampsia symptoms are not missed. It also reduces the need for frequent travel to clinics. Remote monitoring is especially valuable in areas with low maternal health infrastructure. It promotes early diagnosis and safer pregnancies, even in hard-to-reach regions.
Conclusion
The global preeclampsia diagnostics market is growing steadily due to increased awareness of maternal health and the need for early detection. Improved diagnostic tools, such as biomarker blood tests and wearable monitoring devices, are making it easier to identify high-risk pregnancies. Hospitals and healthcare providers are also adopting these tools to improve pregnancy outcomes. Support from government and health organizations is helping to expand diagnostic access, especially in underserved areas. With the integration of digital health solutions and real-time monitoring, early diagnosis is becoming more effective. These combined efforts are expected to improve maternal care and reduce complications linked to preeclampsia globally.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
